Halozyme Therapeutics, Inc. (HALO)
109.86
+2.92
(+2.73%)
USD |
NASDAQ |
Oct 02, 16:00
109.79
-0.07
(-0.06%)
After-Hours: 20:00
Halozyme Therapeutics Market Cap : 12.53B for Oct. 2, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| October 02, 2026 | 12.53B |
| October 01, 2026 | 12.20B |
| September 30, 2026 | 12.59B |
| September 29, 2026 | 12.72B |
| September 28, 2026 | 12.87B |
| September 25, 2026 | 12.99B |
| September 24, 2026 | 13.14B |
| September 23, 2026 | 12.82B |
| September 22, 2026 | 13.13B |
| September 21, 2026 | 12.71B |
| September 18, 2026 | 12.82B |
| September 17, 2026 | 12.51B |
| September 16, 2026 | 12.37B |
| September 15, 2026 | 12.12B |
| September 14, 2026 | 12.31B |
| September 11, 2026 | 12.23B |
| September 10, 2026 | 12.20B |
| September 09, 2026 | 12.25B |
| September 08, 2026 | 12.35B |
| September 04, 2026 | 12.57B |
| September 03, 2026 | 12.63B |
| September 02, 2026 | 12.51B |
| September 01, 2026 | 12.28B |
| August 31, 2026 | 12.14B |
| August 28, 2026 | 12.01B |
| Date | Value |
|---|---|
| August 27, 2026 | 12.19B |
| August 26, 2026 | 12.21B |
| August 25, 2026 | 12.47B |
| August 24, 2026 | 12.39B |
| August 21, 2026 | 12.34B |
| August 20, 2026 | 12.10B |
| August 19, 2026 | 12.27B |
| August 18, 2026 | 11.96B |
| August 17, 2026 | 11.75B |
| August 14, 2026 | 11.25B |
| August 13, 2026 | 11.48B |
| August 12, 2026 | 11.61B |
| August 11, 2026 | 11.70B |
| August 10, 2026 | 11.70B |
| August 07, 2026 | 11.76B |
| August 06, 2026 | 9.780B |
| August 05, 2026 | 9.533B |
| August 04, 2026 | 9.492B |
| August 03, 2026 | 9.751B |
| July 31, 2026 | 9.783B |
| July 30, 2026 | 9.873B |
| July 29, 2026 | 9.871B |
| July 28, 2026 | 9.890B |
| July 27, 2026 | 9.657B |
| July 24, 2026 | 9.711B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| AVITA Medical, Inc. | 393.39M |
| Iovance Biotherapeutics, Inc. | 6.439B |
| Incyte Corp. | 23.17B |
| BioCryst Pharmaceuticals, Inc. | 2.086B |
| Neurocrine Biosciences, Inc. | 14.55B |
Market Cap Related Metrics
| PE Ratio | 32.82 |
| PS Ratio | 7.991 |
| Price to Book Value | 87.28 |
| Price to Free Cash Flow | 16.49 |
| Price | 109.86 |
| Earnings Yield | 3.05% |
| Operating PE Ratio | 14.08 |
| Normalized PE Ratio | 20.17 |